Science

$Deniz Can Guven: Toripalimab phase I data in refractory CCA$

Photo taken from Deniz Can Guven/X

Jan 28, 2025, 06:20

Deniz Can Guven: Toripalimab phase I data in refractory CCA

Deniz Can Guven, The Editorial Board Member of BMC Cancer and Medical Oncologist at Health Sciences University, shared a recent article by Amit Mahipal et al. on X:

“Toripalimab phase I data in refractory CCA:

The first study with Toripalimab in the US.
Manageable side effects.
Acceptable disease control (40%).
Could additional IO options improve access?

“Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study“

Authors: Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony D. Elias, Anthony Shields, Elizabeth Davis, Sant Chawla, Howard Safran, John D. Powderly, Gina D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao and Patricia Keegan

$Deniz Can Guven: Toripalimab phase I data in refractory CCA 1$

More posts featuring Deniz Can Guven.

Amit Mahipal cancer cholangiocarcinoma Christian F Meyer David L. Bajor Deniz Can Guven disease Judy Wang Milind Javle OncoDaily Oncology Patricia Keegan Sheng Yao Todd M Bauer Toripalimab phase I Xiongwen Tang

Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC